Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.

Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol. 2022 Jun; 18(20):2499-2510.

View in: PubMed

collapse authors with profiles


Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)